RHOA and breast neoplasm: In breast tumor cells, cerivastatin exerts its anticancer effects by inhibiting RhoA prenylation, thereby suppressing the RhoA/ROCK pathway and inducing cytoskeletal destabilization, which leads to a loss of traction forces essential for cell migration (85).